Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB307 - Provider product page
- Provider
- R&D Systems
- Product name
- Anti-Human Erythropoietin R Monoclonal Antibody (Clone 38409)
- Antibody type
- Monoclonal
- Antigen
- Mouse myeloma cell line NS0-derived recombinant human Erythropoietin R, Pro26-Pro250
- Description
- Protein A or G purified from ascites
- Reactivity
- Human
- Host
- Mouse
- Antigen sequence
P19235
- Isotype
- IgG
- Vial size
- 500 µg
Submitted references Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.
JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.
Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor.
Patterson SD, Rossi JM, Paweletz KL, Fitzpatrick VD, Begley CG, Busse L, Elliott S, McCaffery I
PloS one 2015;10(3):e0122149
PloS one 2015;10(3):e0122149
JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
De Grandis M, Cambot M, Wautier MP, Cassinat B, Chomienne C, Colin Y, Wautier JL, Le Van Kim C, El Nemer W
Blood 2013 Jan 24;121(4):658-65
Blood 2013 Jan 24;121(4):658-65
Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.
Khankin EV, Mutter WP, Tamez H, Yuan HT, Karumanchi SA, Thadhani R
PloS one 2010 Feb 16;5(2):e9246
PloS one 2010 Feb 16;5(2):e9246
Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor.
Kirkeby A, van Beek J, Nielsen J, Leist M, Helboe L
Journal of neuroscience methods 2007 Aug 15;164(1):50-8
Journal of neuroscience methods 2007 Aug 15;164(1):50-8
No comments: Submit comment
No validations: Submit validation data